BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38428068)

  • 1. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
    Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
    Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
    Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies.
    Kang X; Zhou L; Jian YM; Lan SA; Xu F
    Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
    Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
    Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
    Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
    Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
    Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.
    Takahashi JI; Nakamura S; Onuma I; Zhou Y; Yokoyama S; Sakurai H
    Sci Rep; 2022 Jul; 12(1):11561. PubMed ID: 35798841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line.
    Rao M; Murali S; Amores D; Yu F; Tsourkas A
    Bioconjug Chem; 2024 Jan; 35(1):115-124. PubMed ID: 38173338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.
    Phillips AC; Boghaert ER; Vaidya KS; Mitten MJ; Norvell S; Falls HD; DeVries PJ; Cheng D; Meulbroek JA; Buchanan FG; McKay LM; Goodwin NC; Reilly EB
    Mol Cancer Ther; 2016 Apr; 15(4):661-9. PubMed ID: 26846818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
    Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
    Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.
    Eller JL; Longo SL; Kyle MM; Bassano D; Hicklin DJ; Canute GW
    Neurosurgery; 2005; 56(1):155-62; discussion 162. PubMed ID: 15617598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
    Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
    Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.